What lab or monitoring parameters would you expect to be ordered for a patient on ziprasidone?

• A. Monitor only complete blood count.
• B. Baseline and periodic ECG due to QT prolongation risk; metabolic monitoring (weight, glucose, lipids); liver enzymes as indicated.
• C. No monitoring is needed.
• D. Only renal function tests are required.

Answer: (B)

Ziprasidone requires careful safety monitoring because it carries specific cardiac and metabolic/hepatic risks. The key idea is to protect heart rhythm while watching for metabolic changes and possible liver effects. Baseline and ongoing ECGs are important due to the chance of QT interval prolongation, especially if there are electrolyte disturbances or other QT-prolonging drugs in use. Even though its metabolic impact is generally more favorable than some other antipsychotics, regular metabolic screening is still recommended—tracking weight or BMI, fasting glucose or HbA1c, and fasting lipids to detect early metabolic changes. Since the drug is metabolized in the liver, liver enzymes should be checked as clinically indicated or if signs of liver trouble arise. Relying on only one lab, like a CBC or renal tests, would miss these critical risks, so a broader plan that includes ECG, metabolic monitoring, and liver function tests best ensures safe use.